UB Paderborn / Katalog / Suche / in CDI

The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors

BMC cancer, 2018-07, Vol.18 (1), p.744-744, Article 744

2018

Volltextzugriff (PDF)

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The lancet oncology, 2022-01, Vol.23 (1), p.149-160

2022

Volltextzugriff (PDF)

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial

Journal of clinical oncology, 2020-04, Vol.38 (10), p.1059-1069

2020

Volltextzugriff (PDF)

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial

JAMA oncology, 2017-07, Vol.3 (7), p.906

2017

Volltextzugriff (PDF)

Genetic Ancestry using Mitochondrial DNA in patients with Triple‐negative breast cancer (GAMiT study)

Cancer, 2017-01, Vol.123 (1), p.107-113

2017

Volltextzugriff (PDF)

Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer: A Randomized Pilot Trial

Breast Cancer: Basic and Clinical Research, 2012-01, Vol.2012 (2012), p.39-46

2012

Volltextzugriff (PDF)

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

Clinical breast cancer, 2009-05, Vol.9 (2), p.77-85

2009

Volltextzugriff (PDF)

Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu Status

Modern pathology, 2002-02, Vol.15 (2), p.137-145

2002

Volltextzugriff (PDF)

Metastatic pleomorphic sarcoma to left atrium

Rare tumors, 2009-07, Vol.1 (1), p.e1-3

2009

Volltextzugriff (PDF)

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Volltextzugriff (PDF)

Assessment of HER-2/neu status in breast cancer: Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard

American journal of clinical pathology, 2001-10, Vol.116 (4), p.495-503

2001

Volltextzugriff (PDF)

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

The New England journal of medicine, 2022-02, Vol.386 (6), p.556-567

2022

Volltextzugriff (PDF)

Custodianship of genetic information: Clinical challenges and professional responsibility

Journal of clinical oncology, 2005-03, Vol.23 (9), p.2100-2104

2005

Volltextzugriff (PDF)

Neratinib efficacy in a subgroup of patients with EGFR exon 18 - mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9068-9068

2021

Volltextzugriff (PDF)

Abstract PD1-03: A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR -amplified/ ER+/ HER2-negative metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD1-03-PD1-03

2021

Volltextzugriff (PDF)

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial

JAMA oncology, 2021-11, Vol.7 (11), p.1654

2021

Volltextzugriff (PDF)

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1018-1018

2021

Volltextzugriff (PDF)

The Direct Thrombin Inhibitors: Their Role and Use for Rational Anticoagulation

Hematology/oncology clinics of North America, 2005-02, Vol.19 (1), p.119-145

2005

Volltextzugriff (PDF)

G enetic A ncestry using Mi tochondrial DNA in patients with T riple-negative breast cancer (GAMiT study)

Cancer, 2017-01, Vol.123 (1), p.107-113

2017

Volltextzugriff (PDF)

Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS1115-TPS1115

2019

Volltextzugriff (PDF)

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS1102-TPS1102

2020

Volltextzugriff (PDF)

SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1000-1000

2019

Volltextzugriff (PDF)

MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast

Applied immunohistochemistry & molecular morphology, 2004-12, Vol.12 (4), p.290

2004

Volltextzugriff (PDF)

Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1102-1102

2017

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial

Genetic Ancestry using Mitochondrial DNA in patients with Triple‐negative breast cancer (GAMiT study)

Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer: A Randomized Pilot Trial

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer

Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu Status

Metastatic pleomorphic sarcoma to left atrium

Pembrolizumab for Early Triple-Negative Breast Cancer

Assessment of HER-2/neu status in breast cancer: Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Custodianship of genetic information: Clinical challenges and professional responsibility

Neratinib efficacy in a subgroup of patients with EGFR exon 18 - mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial

Abstract PD1-03: A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR -amplified/ ER+/ HER2-negative metastatic breast cancer (MBC)

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

The Direct Thrombin Inhibitors: Their Role and Use for Rational Anticoagulation

G enetic A ncestry using Mi tochondrial DNA in patients with T riple-negative breast cancer (GAMiT study)

Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer

SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)

MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast

Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01

Suchergebnisse filtern